RANI Borrow Market Update
Rani Therapeutics Holdings (RANI) has been identified as having one of the highest borrow fees among stocks with significant short value. The surge in borrow costs suggests that the supply of shares available for lending is becoming increasingly scarce. For short sellers, this rising cost of carry can significantly impact the profitability of a bearish trade. The current market conditions for RANI indicate that the stock is under heavy scrutiny, and the high borrow fee serves as a warning to traders regarding the potential for increased volatility and the difficulty of maintaining short positions in the current environment.
Signal data sourced from Interactive Brokers. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.